Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy
NCT03731559Phase 2Completed
- Sponsor
- HIV-NAT
- Start
- Jun 2019
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) and Tuberculosis (TB) (2 arms), sponsored by HIV-NAT. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <50 c/mL at 24 weeks. Started Jun 2019; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03731559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731559.